Understanding the barriers to AML care in India.

The steady improvement in outcomes of patients with acute myeloid leukaemia (AML) through the approval and use of novel therapies, advances in supportive care, and better prognostication and disease monitoring has been welcome progress. Unfortunately, this progress has not happened everywhere in the world. In several low-income and middle-income countries (LMICs), such as India, these advances fail to help a substantial proportion of patients because of limited access to haematology services, cost of therapy, deficiencies in comprehensive supportive care, and the unavailability of newer agents.